Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype.

Oncogene - 1 Oct 2022

Kang Synat, Wang Lixin, Xu Lu, Wang Ruiqi, Kang Qingzheng, Gao Xuefeng, Yu Li

Abstract excerpt

NY-ESO-1 is a well-known cancer-testis antigen (CTA) with re-expression in numerous cancer types, but its expression is suppressed in myeloid leukemia cells. Patients with acute myeloid leukemia (AML) receiving decitabine (DAC) exhibit induced expression of NY-ESO-1 in blasts; thus, we investigated the effects of NY-ESO-1-specific TCR-engineered T (TCR-T) cells combined with DAC against AML. NY-ESO-1-specific...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decitabine

Share to Leukemia, Myeloid, Acute

Share to Receptors, Antigen, T-Cell

Share to Receptors, CCR7

Share to T-Lymphocytes

Share to Tumor Necrosis Factor-alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 36097193
DOI: 10.1038/s41388-022-02455-y
PMCID: PMC9568428

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype.PMID 36097193Read ↗

Effective NY-ESO-1–specific MHC II–restricted T cell receptors from antigen-negative hosts enhance tumor regressionSemantic proximity Read ↗

Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapySemantic proximity Read ↗

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatmentSemantic proximity Read ↗

Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-CellsSemantic proximity Read ↗

Two chemotherapeutic agents expand stem-like CD62L+CD8+ T cells in antitumor immune responsesSemantic proximity Read ↗

Eomes+T-betlow CD8+ T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid LeukemiaSemantic proximity Read ↗

Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cellsSemantic proximity Read ↗

Clonal Expansion of Bone Marrow CD8+ T Cells in Acute Myeloid Leukemia Patients at New Diagnosis and Post ChemotherapySemantic proximity Read ↗

Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destructionSemantic proximity Read ↗

Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in Acute Myeloid LeukemiaSemantic proximity Read ↗

Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for LeukemiaSemantic proximity Read ↗

Adoptive NK cell therapy in AML: progress and challengesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.